Cyclerion Therapeutics Profit Margin

Cyclerion Therapeutics (CYCN) currently reports a profit margin of -353.0% as of June 2026. That compares with -56.26% in the prior-year period — down 527.5% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Cyclerion Therapeutics's profit margin history and peer comparisons.

Cyclerion Therapeutics's profit margin decreased from -56.26% to -353.0% — a 527.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cyclerion Therapeutics's profit margin of -353.0% is lower than the Healthcare sector average of 14.34%. That is roughly 2560.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cyclerion Therapeutics's current -353.0% should be judged against Healthcare norms (sector average: 14.34%) and against CYCN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -353.0%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Cyclerion Therapeutics, and consider following CYCN for alerts when major investors trade the stock.